Finance

Lists
Q3 2026 earnings • released • EPS beat +8.82% • Revenue beat +3.25%
See results
NOVN:SWX
Novartis AG
CHF 132.30
+2.38%
(+3.08) 1D
Oct 29, 5:30:41 PM GMT+1  ·   CHF
All symbols
SymbolPriceChange% Change
Generating top insights for NOVN...
Open
CHF 130.76
High
CHF 134.36
Low
CHF 130.12
Mkt. cap
268.85B
Avg. vol.
3.28M
Volume
6.12M
Dividend
2.80%
Quarterly dividend
CHF 0.93
Ex-dividend date
Mar 10, 2026
P/E ratio
24.10
52-wk high
CHF 134.36
52-wk low
CHF 97.05
EPS
CHF 5.49
Shares outstanding
2.03B
No. of employees
75K
Open
CHF 130.76
High
CHF 134.36
Low
CHF 130.12
Mkt. cap
268.85B
Avg. vol.
3.28M
Volume
6.12M
Dividend
2.80%
Quarterly dividend
CHF 0.93
Ex-dividend date
Mar 10, 2026
P/E ratio
24.10
52-wk high
CHF 134.36
52-wk low
CHF 97.05
EPS
CHF 5.49
Shares outstanding
2.03B
No. of employees
75K
News stories
From web sources and news partners
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3K
FoundedMar 7, 1996
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websitenovartis.com
Last report
Oct 27, 2026
Fiscal period
Q3 2026
$2.46 / $2.26
+8.82%beat
Revenue / Est. (USD)
15.03B / 14.56B
+3.25%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
14.36B
13.86B
13.52B
14.95B
Cost of goods sold
3.54B
3.54B
3.44B
3.68B
Cost of revenue
3.54B
3.54B
3.44B
3.68B
Research and development expenses
2.86B
2.84B
2.78B
2.74B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.30B
3.44B
3.14B
3.23B
Operating expense
6.24B
6.46B
5.96B
6.10B
Total operating expenses
9.77B
10.00B
9.40B
9.78B
Operating income
4.58B
3.86B
4.12B
5.18B
Other non operating income
-7.00M
-130.00M
4.00M
19.00M
EBT including unusual items
4.20B
3.22B
3.84B
4.27B
EBT excluding unusual items
4.29B
3.49B
3.78B
4.73B
Income tax expense
266.00M
814.00M
683.00M
1.01B
Effective tax rate
6.34%
25.30%
17.79%
23.71%
Other operating expenses
70.00M
190.00M
42.00M
127.00M
Net income
3.93B
2.41B
3.16B
3.26B
Net profit margin
27.36%
17.38%
23.34%
21.83%
Earnings per share
2.25
2.03
1.99
2.41
Interest and investment income
-
373.00M
-
-
Interest expense
-281.00M
-304.00M
-343.00M
-462.00M
Net interest expenses
-281.00M
69.00M
-343.00M
-462.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.78B
4.96B
5.24B
6.30B
Gain or loss from assets sale
81.00M
80.00M
-159.00M
-247.00M
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps